TEVA PHARMACEUTICAL FIN LLC - DBCV 0.250% 2/0 Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2022

Type / Class
Debt / DBCV 0.250% 2/0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of TEVA PHARMACEUTICAL FIN LLC - DBCV 0.250% 2/0 across Reporting Periods

Period Principal Value Change Price (% of par) (Median) Investors
2022 Q4 $0 $0 -$17,604,000 0
2022 Q3 $22,103,000 $17,605,593 +$12,000 79.65% 9
2022 Q2 $22,083,000 $21,504,948 -$209,000 100.0% 9
2022 Q1 $22,297,898 $21,796,955 -$15,388,000 98.88% 10
2021 Q4 $37,858,000 $37,132,950 -$40,000 99.0% 11
2021 Q3 $25,305,000 $24,924,966 +$2,956,000 99.84% 10
2021 Q2 $22,339,680 $22,008,970 -$2,942,000 99.87% 10
2021 Q1 $25,308,000 $25,235,996 -$459,386,351 100.0% 11
2020 Q4 $487,265,640 $485,318,710 -$192,336 99.5% 45
2020 Q3 $419,368,465 $410,283,228 +$31,372,685 98.02% 46
2020 Q2 $398,604,472 $388,810,196 +$2,236,901 97.81% 46
2020 Q1 $395,159,955 $371,374,363 -$14,265,489 93.05% 52
2019 Q4 $363,832,783 $346,437,566 -$20,128,350 94.87% 53
2019 Q3 $380,353,776 $346,486,002 -$7,543,487 90.94% 56
2019 Q2 $388,968,722 $356,448,686 +$9,004,471 91.59% 55
2019 Q1 $378,391,801 $351,177,625 -$492,626 92.63% 47
2018 Q4 $379,145,801 $344,249,220 -$28,980,281 90.25% 47
2018 Q3 $406,709,306 $381,511,560 -$516,613 93.57% 50
2018 Q2 $421,217,914 $390,674,628 +$17,073,301 92.7% 55
2018 Q1 $403,156,285 $355,394,283 -$12,627,997 88.08% 56
2017 Q4 $413,202,564 $363,891,303 -$36,272,462 88.25% 58
2017 Q3 $448,054,146 $405,099,908 -$42,709,307 90.14% 47
2017 Q2 $491,229,027 $528,155,107 +$21,346,627 107.26% 43
2017 Q1 $471,355,027 $505,139,108 +$35,742,943 107.3% 42
2016 Q4 $437,332,294 $481,729,000 -$17,148,777 109.51% 41
2016 Q3 $434,295,986 $517,998,000 -$9,148,146 119.31% 40
2016 Q2 $438,369,705 $550,716,000 +$24,253,916 125.36% 38
2016 Q1 $423,191,262 $550,968,500 -$22,857,744 130.14% 44
2015 Q4 $446,259,722 $698,114,537 -$9,746,273 156.33% 47
2015 Q3 $457,074,378 $618,807,068 +$7,333,224 135.63% 49
2015 Q2 $441,384,909 $620,318,886 +$63,106,286 139.86% 51
2015 Q1 $403,261,935 $598,778,599 +$119,871,332 148.03% 45
2014 Q4 $323,575,772 $449,899,146 -$92,665,808 136.7% 43
2014 Q3 $395,023,539 $508,167,000 -$19,044,296 128.4% 42
2014 Q2 $406,024,869 $521,044,000 +$25,177,856 127.96% 41
2014 Q1 $361,271,825 $460,042,000 -$5,392,994 126.94% 37